MVC-COV1901, a high-end vaccine, was selected for the WHO New Coronary Pneumonia Solidarity Test Vaccine

Taipei, October 28, 2021/PRNewswire/ - The vaccine candidate MVC-COV1901 of Medigen Vaccine Biologics Corp ("High-end Vaccine") was recommended by an independent vaccine priority advisory group to be included in the world The Solidarity Vaccine Trial (STv) of the World Health Organization (WHO)
.

After the external advisory group reviewed about 20 candidate vaccines, the high-end vaccine was finally selected and became one of the two vaccines participating in the global solidarity trial

The WHO issued this announcement after the WHO Ethics Review Committee and relevant regulatory agencies and ethics committees in Colombia, Mali and the Philippines approved the continuation of this research
.

Major researchers and research teams in each clinical site and their respective countries have begun to recruit volunteers to participate in the trial

This is an international randomized clinical trial platform designed to quickly evaluate the effectiveness and safety of potential new vaccine candidates and help build a larger vaccine portfolio to protect people around the world from new coronary pneumonia.
Invasion
.

High-end vaccines began to develop their own vaccines in February 2020, hoping to propose a solution that will help end this menacing epidemic to a certain extent
.

MVC-COV1901 is a subunit vaccine that uses recombinant S-2P antigen and uses CpG 1018 and aluminum hydroxide provided by Dynavax as adjuvants

Chen Canjian, vice chairman and general manager of High-end Vaccine Biologics Co.
, Ltd.
, said: "We are very excited to be selected for the WHO International Solidarity Test Vaccine against the New Coronavirus
.

We have been working hard to develop a vaccine with minor side effects and actively protect the public.

As the battle against the new crown epidemic continues, the demand for effective vaccines remains high
.

High-end vaccine believes that the company has the ability, corresponding infrastructure and expertise to contribute to the realization of global vaccine protection

Introduction to MVC-COV1901

MVC-COV1901 is a subunit vaccine that uses recombinant S-2P antigen and uses CpG 1018 and aluminum hydroxide provided by Dynavax as adjuvants
.

The S-2P antigen is a trimer developed by the US National Institutes of Health (US NIH), a recombinant spike protein that is stable before fusion

Introduction to High-end Vaccine Biologics Co.
, Ltd.
(High-end Vaccine)

High-end Vaccine Biologics Co.
, Ltd.
is a biopharmaceutical company that uses cell culture technology to develop new vaccines and biosimilars
.

In line with the goal of local vaccine self-sufficiency, high-end vaccines aim to provide vaccines and biopharmaceuticals to meet regional needs, and hope to help deal with the threat of infectious diseases globally